Molecular Biomarker Testing for Noncancer Indications - MEDICAID - FLORIDA (Revised)
Humana Florida Medicaid has revised its molecular biomarker testing policy for noncancer indications, effective September 2, 2026. The policy explicitly denies coverage for Gene Expression Profiling (GEP) for coronary artery disease (CPT 81493) and Multianalyte Assay with Algorithmic Analysis (MAAA) for rheumatoid arthritis risk prediction (CPT 81490), citing insufficient evidence. However, molecular pathology testing (CPT 81479) and unlisted MAAA (CPT 81599) remain eligible for coverage when they meet specific clinical validity criteria.